ºñ¼Ò¼¼Æ÷¼º Æó¾ÏÀÇ ¹æ»ç¼± Ä¡·á ¼ºÀû
Short-Term Results of Non-Small Cell Lung Cancer with Curative Radiotherapy

´ëÇÑÄ¡·á¹æ»ç¼±°úÇÐȸÁö 1990³â 8±Ç 2È£ p.213 ~ p.218

¾È¼ºÀÚ(Ahn Sung-Ja) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ Ä¡·á¹æ»ç¼±°úÇб³½Ç
¹Ú½ÂÁø(Park Seung-Jin) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ Ä¡·á¹æ»ç¼±°úÇб³½Ç
Á¤¿õ±â(Chung Woong-Ki) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ Ä¡·á¹æ»ç¼±°úÇб³½Ç
³ªº´½Ä(Nah Byung-Sik) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ Ä¡·á¹æ»ç¼±°úÇб³½Ç

Abstract

1985³â 8¿ùºÎÅÍ 1988³â 10¿ù±îÁö Àü³²´ëÇб³º´¿ø Ä¡·á¹æ»ç¼±°ú¿¡¼­ ±ÙÄ¡¸ñÀûÀÇ ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº ºñ¼Ò¼¼Æ÷¼º Æó¾ÏȯÀÚ 102¸í¿¡ ´ëÇÏ¿© ÈÄÇâÀû ºÐ¼®À» ½ÃÇàÇÏ¿´´Ù. ´ë»óȯÀڵ鿡 ´ëÇÑ ÃßÀûÁ¶»ç±â°£Àº 1°³¿ù¿¡¼­ 37°³¿ùÀ̾ú°í Áß°£°ªÀº 15°³¿ùÀ̾ú´Ù.
ÀüüȯÀÚ±ºÀÇ 1³â ¹× 2³â »ýÁ¸À²Àº °¢°¢ 28%, 5%¿´À¸¸ç ÀÓ»óÀû º´±âº°·Î º¸¸é ¥±, ¥²A, ¥²B±â ȯÀÚ±ºÀÇ Æò±Õ»ýÁ¸±â°£Àº °¢°¢ 10°³¿ù, 6°³¿ù, 9°³¿ùÀ̾ú°í 2³â »ýÁ¸À²Àº °¢°¢ 12.5%, 12.1%, 0%¿´´Ù.
¹æ»ç¼±Ä¡·áÈÄ Ä¡·á½ÇÆа¡ È®ÀÎµÈ 32¸í¿¡ ´ëÇÏ¿© ºÐ¼®À» ÇÏ¿©º¸¸é ±¹¼Ò½ÇÆбºÀÌ 28%(9¸í)¿´À¸¸ç ¿ø°Ý½ÇÆбºÀÌ 72%(23¸í)·Î Æó¾ÏȯÀÚÀÇ »ç¸ÁÀÇ ´ëºÎºÐÀº Àü½ÅÀûÀÎ ¿ø°ÝÀüÀÌ¿¡ ÀÇÇÔÀ» ¾Ë ¼ö ÀÖ¾ú´Ù. Ä¡·á´ç½ÃÀÇ Àü½ÅÀû °Ç°­»óÅ´ »ýÁ¸À²¿¡ À¯ÀÇÇÑ ¿µÇâÀ» ÁÖ¾úÀ¸³ª(p<0.01), ¹æ»ç¼± Ä¡·á¼±·®¿¡ µû¸¥ »ýÁ¸À²ÀÇ À¯ÀÇÇÑ Â÷ÀÌ´Â º¸ÀÌÁö ¾Ê¾Ò´Ù(p>0.05).
A retrospective analysis was performed on 102 patients with non-small cell lung cancer who received the curative radiotherapy from August 1985 to October 1988 at the Department of Therapeutic Radiology of Chonnam University Hospital. The follow-up period was ranged from 1 to 37 months and the median follow-up time was 15 months. The acturial 1 and 2 year survival rate of all the patients was 28% and 5%, respectively. The median survival was 10 months for stage ¥±, 6 months for stage ¥²A, and 9 for ¥²B and the actuarial 2 year survival tate was 12.5%, 12.1%, and 0% respectively. The treatment failure was identified in 32 patients and the locoregional failure was seem in 9 patients (28%) and the distant failure in 23 patients (72%). The initial performance status was related to the survival with statistical significance (p<0.01), but the survival difference by the radiation dose was not statistically significant (p>0.05).

Å°¿öµå

Non-small cell lung cancer, Radiotherapy, Survival
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
The acturial 1 and 2 year survival rate of all the patients was 28% and 5%, respectively; The median survival was 10 months for stage ¥±, 6 months for stage ¥²A, and 9 for ¥²B and the actuarial 2 year survival tate was 12.5%, 12.1%, and 0% respectively.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå